Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: HIV-1 Gag p24

Search for Biomarkers

Analyte:

HIV-1 Gag p24

Platform:

Matrix:

Human Serum

Status:

Experienced Running

Sensitivity-LLOQ/ULOQ:

LLOQ: 3.93 pg/mL

Biological or Clinical Significance:

HIV-1 Gag is produced in vast quantities during an infection and is capable of forming virus-like particles in the absence of other viral components. Gag p24, the major capsid protein of the HIV-1 virion, has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different isolates.

It is also well known that HIV infection causes CTL escape mutants of p24, which results in a loss of binding of CTL epitopes either to MHC class I molecules or to the T-cell receptor on CD8+ T cells. Mutations in CTL epitopes and escape from CTL recognition are not unique to HIV and have also been reported for other viruses. However, the effect of impaired antigen processing and presentation of HIV-1 antigens on the generation of CTL escape mutants has not been fully elucidated.

References:

Speak to a Scientist

















What would you like to discuss?

With whom will we be speaking?






I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.


biomarker services

Services

See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

Explore our services

case studies

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Read our case studies